[24] Despite such a pronounced placebo effect in the present study, patients on tolterodine demonstrated consistently greater improvements in micturition diary variables compared with placebo.

Tolterodine is contraindicated in patients who are allergic to the drug, with urinary retention, functional or structural gastrointestinal problems that reduce motility, increased eye pressure ...

The symptoms began several weeks after she began to take tolterodine (2 mg twice daily) for urinary incontinence. These hallucinations did not distress the patient and resolved after three months ...

Discover comprehensive details about Tolterodine, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

Product Approvals and Launches Media Clinical Spotlight ...

Monthly discontinuation rates werederived from a cohort of newly treated patients withOAB (tolterodine ER, n = 15 394 or oxybutynin ER,n = 7934). All were assumed to be receiving therapyfor at ...

New York, November 4, 2004 – Combination therapy with Pfizer Inc's DETROL® LA (tolterodine tartrate extended release capsules) and an alpha blocker, a standard treatment for enlarged prostate ...

Mylan announced it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) of Tolterodine Tartrate Extended-Release (ER) Capsules, the generic version of Pfizer ...

Tolterodine tartrate 2mg, 4mg; ext-rel caps. Swallow whole. 4mg once daily; may decrease to 2mg once daily. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir), or ...

After 12 weeks' treatment, the mean number of incontinence episodes decreased by 10.6 episodes per week (-46%) in the tolterodine treatment group. This decrease was significant not only compared ...